147 related articles for article (PubMed ID: 15266095)
21. Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics.
Economopoulos T; Asprou N; Stathakis N; Papageorgiou E; Dervenoulas J; Xanthaki K; Raptis S
Leuk Lymphoma; 1996 Mar; 21(1-2):131-6. PubMed ID: 8907280
[TBL] [Abstract][Full Text] [Related]
22. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
Sandlund JT; Murphy SB; Santana VM; Behm F; Jones D; Berard CW; Furman WL; Ribeiro R; Crist WM; Greenwald C; Chen G; Walter A; Pui CH
J Clin Oncol; 2000 Aug; 18(16):3018-24. PubMed ID: 10944136
[TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
[TBL] [Abstract][Full Text] [Related]
24. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
25. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
27. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
29. [Prognosis analysis of 53 cases with primary intestinal non-Hodgkin's lymphoma].
Xiang XJ; He YJ; Li YH; Huang HQ; Xia ZJ; Huang H
Ai Zheng; 2004 Apr; 23(4):443-7. PubMed ID: 15087036
[TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic analysis of 125 cases of non-Hodgkin's lymphoma.
Liu L; Zhang M; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):547-50. PubMed ID: 18549626
[TBL] [Abstract][Full Text] [Related]
31. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
32. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
[TBL] [Abstract][Full Text] [Related]
33. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
34. Prognostic markers in malignant lymphoma: an analysis of 1,198 patients treated at a single centre.
Low SE; Horsman JM; Hancock H; Walters SJ; Hancock BW
Int J Oncol; 2001 Dec; 19(6):1203-9. PubMed ID: 11713590
[TBL] [Abstract][Full Text] [Related]
35. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
39. CA 125, a New Prognostic Marker for Aggressive NHL.
Abd El Gawad IA; Shafik HE
J Egypt Natl Canc Inst; 2009 Sep; 21(3):209-17. PubMed ID: 21132031
[TBL] [Abstract][Full Text] [Related]
40. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
Li D; Li G; Wang B
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]